Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
about
Stabilization of high-risk plaquesAdvances in the Study of the Antiatherogenic Function and Novel Therapies for HDLNew Era of Lipid-Lowering DrugsEgg phospholipids and cardiovascular healthThe cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effectsHDL-apoA-I exchange: rapid detection and association with atherosclerosisSite-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteinsCholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.Impact of self-association on function of apolipoprotein A-INovel HDL-directed pharmacotherapeutic strategies.The "beta-clasp" model of apolipoprotein A-I--a lipid-free solution structure determined by electron paramagnetic resonance spectroscopy.Novel Pathways of Apolipoprotein A-I Metabolism in High-Density Lipoprotein of Different Sizes in HumansTargeting high density lipoproteins in the prevention of cardiovascular disease?HDL, Atherosclerosis, and Emerging TherapiesAn abundant dysfunctional apolipoprotein A1 in human atheroma.ABC transporters, atherosclerosis and inflammation.Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?Update on HDL receptors and cellular cholesterol transport.New lipid-lowering drugs: an update.Thyroid hormone enhances the ability of serum to accept cellular cholesterol via the ABCA1 transporter.Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.ApoA-I-Directed Therapies for the Management of Atherosclerosis.Apolipoprotein A-I: A Molecule of Diverse Function.High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol.
P2860
Q26738584-B4E8B67A-13C0-4DEE-9BEF-7667F49F0B48Q26801507-3864C73F-7066-4BC0-BB96-730DD52E6C62Q28072298-FD7FF399-946D-4D26-8C7D-3606B91B63B6Q28082796-41225B08-A06B-40EB-AC30-8B1D25034F5FQ28388695-08633CEB-D911-49B2-ACF3-EAAC9896E043Q28535779-E7FC23EF-504E-4A3A-AC2C-60B5E271B2AFQ33675617-317991B0-7F0B-44EC-A58A-5E426104BA10Q33897950-1462FFA1-82FA-4CAF-8966-D658EDC6740BQ34155049-09057B70-0AB9-4766-B505-82E23BA98DEFQ34781496-0D247F89-DBDC-4631-BB4B-54CA5E513FD9Q35371440-2FED9358-520C-435E-8BCD-7576C214ADF6Q35860020-A02D042F-32C7-45AA-B84D-534E087402DEQ36109412-8591FBC4-5839-47CF-A306-29B2AA4D0F76Q36403156-3F7F2D78-2843-41F5-BD60-D855C6B14240Q36453173-981F42FE-3D32-438E-936B-29F5D412854AQ36918309-2B26594A-D19F-4D6D-A2C4-297B0DE2AB1BQ37581580-DCB86291-AB75-4092-95B7-3D1EC91F9D01Q37688500-359661F5-8DC8-4083-B0DA-F3AD89A947B5Q37702199-E8ACEC4D-F1C6-4562-AA2C-D91D4D3960DBQ37707402-351EB707-BFC4-4AC5-BDC7-ABCD25498F45Q37837679-32834D07-B722-4A98-B21D-E00A36C4E997Q37984782-4DA44EBF-761C-4DEA-9116-3C24FE2830DCQ38334939-90695823-0232-4B60-8179-FA42E563A50CQ38363617-5C76057B-BC49-4FFE-839B-8CB4EECDBBF3Q38579703-EA941908-43EC-48A8-9E80-7C10D56F5293Q38844884-18FAEE32-CD68-453C-B7E0-B7FDB27E8950Q38965138-7989246A-BA0C-4D51-AF53-E0076E59D01CQ39442094-BB14D807-8FC1-4453-9B76-02BB20CCB7E3Q42126715-5C129BE7-2E52-4ECE-88A6-9F5C4B26E257Q42131230-A5484563-80EA-4CCA-B401-960B5DC3FF49Q45870343-A61DC9F6-BBF0-4F7C-BE8D-44B8443D03C8
P2860
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@en
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@nl
type
label
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@en
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@nl
prefLabel
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@en
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@nl
P2093
P2860
P1476
Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.
@en
P2093
Adam Conner
Bela Asztalos
Chunyu Zheng
Frank M Sacks
George Rothblat
Gerhard Kostner
H Bryan Brewer
Hassibullah Akeefe
Jo-Ann B Maltais
Lawrence L Rudel
P2860
P304
P356
10.1194/JLR.M800622-JLR200
P577
2009-01-14T00:00:00Z